California Doc's DEA Reg Revoked Over State License Issues
Published Date: 5/7/2025
Notice
Summary
Dr. Edmund Ayoub Jr. from California lost his DEA registration because he no longer has the legal right to handle controlled substances in his state. Despite multiple attempts, he didn’t respond or ask for a hearing, so the DEA officially revoked his registration. This means he can’t prescribe or manage controlled drugs anymore, effective immediately, impacting his medical practice and any related income.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 2 costs, 0 mixed.
DEA Registration Revoked for Dr. Ayoub
The DEA revoked Certificate of Registration No. FA0321036 for Edmund Ayoub Jr., M.D., meaning he may no longer prescribe, administer, dispense, or otherwise handle controlled substances. The revocation is effective June 6, 2025 and will directly affect his medical practice and any related income.
Pending DEA Applications Denied
The Order denies any pending applications of Edmund Ayoub Jr., M.D., to renew or modify Certificate of Registration No. FA0321036 and denies any other pending application for additional registration in California. This denial accompanies the revocation and prevents immediate restoration or expansion of DEA registration in California.
15-Day Reconsideration Window
The Order states that the registrant may file a properly supported motion for reconsideration of the findings of fact within fifteen calendar days of the date of the Order. Any such motion and response must be filed and served by email to the other party and to the DEA Office of the Administrator.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-11572 — Ashley Vermillion, N.P.; Decision and Order
Ashley Vermillion, a nurse practitioner from Maine, lost her DEA registration because she no longer has the legal right to handle controlled substances in her state. She didn’t ask for a hearing, so the DEA moved forward and officially revoked her registration. This means she can’t prescribe or manage controlled drugs anymore, effective immediately.
2026-11416 — Importer of Controlled Substances Application: CalCog Inc.
CalCog Inc. wants to become an official importer of some powerful controlled substances like LSD and 5-MeO-DMT. People and companies involved with these drugs have until July 8, 2026, to share their thoughts or ask for a hearing. This move could shake up the import scene, but no costs or changes happen until the DEA decides.
2026-10380 — Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
The DEA wants to put diphenidine, a drug, into Schedule I, which means it will be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or owns diphenidine, adding strict rules and penalties. You’ve got until June 25, 2026, to share your thoughts before the new rules might kick in.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
Previous / Next Documents
Previous: 2025-07934 — Margaret Dennis, D.M.D.; Default Decision and Order
Dr. Margaret Dennis from Jacksonville, FL, lost her DEA license because she prescribed controlled drugs without proper medical reasons and ignored warning signs for over 11 years. Since she didn’t ask for a hearing, her license is officially revoked to protect public safety. This means she can’t legally prescribe these drugs anymore, effective immediately.
Next: 2025-07936 — Mohan Kaza, M.D.; Default Decision and Order
Dr. Mohan Kaza from Michigan had his DEA license suspended and is now losing it for giving out strong prescription drugs without proper exams or checks. He also coached undercover agents to lie and charged extra fees for higher doses. This decision protects public safety by stopping unsafe prescribing practices immediately.